Presentation of Sobi's Interim Report for January - March, 2011
(Thomson Reuters ONE) -
Welcome to a presentation of Swedish Orphan Biovitrum's first quarter results
2011, to be held on April 20 at 3 p.m. (CET). The report will be published the
same day at 8.30 a.m. (CET).
The presentation will be hosted by CEO Kennet Rooth and CFO Lars Sandström and
will be web casted.
Registration:
Please register for participation to Marianne Gripe onmarianne.gripe(at)sobi.com or
by telephone +46 (0)8 697 34 27.
Venue: Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm (Sweden)
Coffee will be served
To participate through conference call or web cast :
The presentation will be web casted live at our web sitewww.sobi.com.
Conference call dial in: UK: +44 (0)20 3043 2436, US: +1 866 458 40 87, SE: +46
(0)8 505 598 53
The presentation will be published on our web site after the meeting as will the
archived web cast, please go to: www.sobi.com.
Åsa Stenqvist, VP Communications and Investor Relations
Phone: +46 8 697 20 00
About Swedish Orphan Biovitrum (Sobi)
Sobi is a Swedish based niche specialty pharmaceutical company with an
international market presence. The company is focused on providing and
developing specialist pharmaceuticals for rare disease patients with high
medical needs. The portfolio consists of about 60 marketed products and an
emerging late stage clinical development pipe-line. Our focus areas are:
hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer
supportive care and inherited metabolic disorders. In 2010 Sobi had revenues of
about SEK 1.9 B and approximately 500 employees. The share (STO: SOBI) is listed
on NASDAQ OMX Stockholm. For more information please visitwww.sobi.com.
Press release in PDF format:
http://hugin.info/134557/R/1505444/440330.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1505444]
Unternehmensinformation / Kurzprofil:
Datum: 12.04.2011 - 10:50 Uhr
Sprache: Deutsch
News-ID 53414
Anzahl Zeichen: 2577
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 209 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Presentation of Sobi's Interim Report for January - March, 2011"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
